Organovo Holdings, Inc. Files S-1 Registration Statement

TL;DR

<b>Organovo Holdings, Inc. has filed an S-1 registration statement, indicating potential future public offerings.</b>

AI Summary

ORGANOVO HOLDINGS, INC. (VIVS) filed a IPO Registration (S-1) with the SEC on April 12, 2024. Organovo Holdings, Inc. (formerly Real Estate Restoration & Rental, Inc.) filed an S-1 registration statement on April 12, 2024. The company's fiscal year ends on March 31. Organovo Holdings, Inc. is incorporated in Delaware. The company's business and mailing address is 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121. The filing is made under the Securities Act of 1933.

Why It Matters

For investors and stakeholders tracking ORGANOVO HOLDINGS, INC., this filing contains several important signals. This S-1 filing signals Organovo's intent to potentially raise capital through public markets, which could impact its financial structure and growth trajectory. The filing provides updated information on the company's business, financial condition, and management, crucial for investors considering future investments.

Risk Assessment

Risk Level: medium — ORGANOVO HOLDINGS, INC. shows moderate risk based on this filing. The company has a history of name changes and is filing an S-1, which is a registration statement for securities, suggesting potential future equity offerings and associated risks.

Analyst Insight

Monitor future filings for details on any proposed stock offerings, pricing, and use of proceeds.

Key Numbers

• S-1 — Form Type (Filing form type)
• 1933 Act — SEC Act (Securities Act under which the filing is made)
• 278668 — SEC File Number (SEC file number associated with the filing)
• 0331 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• ORGANOVO HOLDINGS, INC. (company) — Filer name
• REAL ESTATE RESTORATION & RENTAL, INC. (company) — Former company name
• 11555 SORRENTO VALLEY ROAD (company) — Business address street 1
• SUITE 100 (company) — Business address street 2
• SAN DIEGO (company) — Business address city
• CA (company) — Business address state
• 92121 (company) — Business address zip
• 2024-04-12 (date) — Filing date

FAQ

Risk Factors

• Registration Statement Filing [medium — regulatory]: The filing of an S-1 registration statement indicates the company's intent to offer securities, which is subject to regulatory review and market conditions.

Industry Context

Organovo Holdings operates in the biotechnology sector, focusing on biological products.

Regulatory Implications

The S-1 filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1 filing for detailed financial statements and risk factors.
2. Track subsequent SEC filings for updates on any proposed securities offerings.
3. Analyze the company's business strategy and market position within the biotechnology industry.

Key Dates

• 2024-04-12: S-1 Filing — Indicates intent for potential public offering of securities.
• 2010-07-22: Name Change — Company formerly known as Real Estate Restoration & Rental, Inc.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against.

Key Financial Figures

• $0 — d to the public in this offering, minus $0.001, and the exercise price of each pre
• $0.001 — rice of each pre-funded warrant will be $0.001 per share. The pre-funded warrants will
• $2.9 million — h and cash equivalents of approximately $2.9 million. The estimated preliminary cash and c
• $4.35 — average exercise price of approximately $4.35 per share; 123,892 shares of common s

Filing Documents

• onvo-20240412.htm (S-1) — 3940KB
• onvo-ex23_1.htm (EX-23.1) — 4KB
• onvo-exfiling_fees.htm (EX-FILING FEES) — 44KB
• img64644474_0.jpg (GRAPHIC) — 13KB
• img64644474_1.jpg (GRAPHIC) — 8KB
• img64644474_2.jpg (GRAPHIC) — 13KB
• img64644474_3.jpg (GRAPHIC) — 8KB
• 0000950170-24-044137.txt (&nbsp;) — 11865KB
• onvo-20240412.xsd (EX-101.SCH) — 1348KB
• onvo-20240412_htm.xml (XML) — 1952KB

Use of Proceeds

Use of Proceeds 32 Capitalization 33

Management's Discussion and Analysis of Financial Condition and Results of Operation

Management's Discussion and Analysis of Financial Condition and Results of Operation 41 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 50

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 51

Description of Capital Stock

Description of Capital Stock 52 Management 56 Director Compensation 59

Executive Compensation

Executive Compensation 60 Equity Compensation Plan Information 67 Certain Relationships and Related Party Transactions 69 Principal Stockholders 69 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 71 Plan of Distribution 75 Legal Matters 77 Experts 77 Where You Can Find More Information 77 Disclosure of Commission Position on Indemnification for Securities Act Liabilities 78 i About this Prospectus You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information other than the information that we have provided or incorporated by reference in this prospectus and your reliance on any unauthorized information or representation is at your own risk. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus, or any sale of our common stock. Our business, financial condition and results of operations may have changed since those dates. The information appearing in this prospectus and any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of its respective date, regardless of the time of delivery of the respective document or of any sale of securities covered by this prospectus. You should not assume that the information contained in this prospectus, or in any free writing prospectus that we have authorized for use in connection with this offering, is accurate as of any date other than the respective dates thereof. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, includi

Use of proceeds

Use of proceeds We intend to use the net proceeds from this offering for working capital and general corporate purposes, which could include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, legal expenditures, including intellectual property protection and maintenance expenditures, acquisitions of new technologies and investments, business combinations and the repurchase of capital stock. See " Use of Proceeds " on page 32 for more information.

Risk factors

Risk factors Investing in our securities involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment. You should carefully consider the information set forth in the " Risk Factors " section beginning on page 10. Nasdaq Capital Market trading symbol Our common stock is listed on the Nasdaq Capital Market under the symbol "ONVO." There is no established trading market for the pre-funded warrants, and we do not expect a trading market to develop. We do not intend to list the pre-funded warrants on any securities exchange or other trading market. Without a 3 trading market, the liquidity of the pre-funded warrants will be extremely limited. The number of shares immediately outstanding following this offering is based on 9,838,755 shares of common stock outstanding as of December 31, 2023 and also gives effect to 237,712 shares of our common sold and issued through an "at the market" offering" pursuant to a Sales Agreement that we entered into with H.C. Wainwright & Co., LLC and JonesTrading Institutional Services LLC on March 16, 2018 (the "Sales Agreement") and excludes: 695,459 shares of common stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of approximately $4.35 per share; 123,892 shares of common stock issuable upon the vesting and settlement of outstanding restricted stock units; 1,000 shares of common stock available for issuance pursuant to the 2021 Inducement Equity Plan; 1,643,798 shares of common stock available for issuance pursuant to the 2022 Equity Incentive Plan; and 45,000 shares of common stock available for issuance pursuant to the 2023 Employee Stock Purchase Plan. Unless otherwise indicated, all information in this prospectus assumes no exercise of options under our equity incentive plans and no exercise of pre-funded warrants. 4 Summary Financial Data The following tables set forth our summary statements of operatio

View Full Filing

View this S-1 filing on SEC EDGAR